When it comes to drug patents, the stakes are much higher than the profits of big pharma, which is why we should be concerned about the current Trans Pacific Partnership negotiations, writes Jon Edwards.
In Malaysia, Peru, Indonesia, Papua New Guinea and throughout the Pacific rim region, millions of people struggle with debilitating and life-threatening diseases. With the globalisation of communication, sufferers know that there are effective treatments for these diseases, but for so many, these treatments are priced out of reach or are simply not available.
The current negotiations of the Trans Pacific Partnership (TPP) trade agreement threaten to make this deplorable situation worse.
Read the full article >
Image: Medicine Bottle / Shutterstock